30+ Presentations from Top Pharma at Drug Discovery Chemistry 2024
As in the past, speaker participation by industry is once again very strong, with presentations from AbbVie, Astex Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Genentech, GlaxoSmithKline, Janssen Pharmaceuticals, Merck, Novartis, Pfizer, Sanofi, and more. Preview some of the 30+ presentations* below:
Targeting MYC:MAX—Intramolecular Interactions Involving Intrinsically Disordered Regions Provide New Biological Insights
Wolfgang Jahnke, PhD, Director Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research
Targeting the Hippo Pathway in Cancers
Anwesha Dey, PhD, Director & Distinguished Scientist, Discovery Oncology, Genentech, Inc.
Leveraging Our File to Find Novel Ligands for an E3 Ligase
Matthew Calabrese, PhD, Senior Director & Head, Structural & Molecular Sciences, Pfizer Global R&D
Peptidic Macrocycles as Suitable Bioactive Scaffold for Targeted Protein Degradation
Jakob Fuhrmann, PhD, Senior Principal Scientist, Peptide Therapeutics, Genentech, Inc.
Assessing Highly Diverse Fragment Libraries by 19F NMR Enables Robust Identification of Chemical Starting Points for Challenging Drug Targets
Andreas Lingel, PhD, Senior Principal Scientist, Global Discovery Chemistry, Novartis Institutes for Biomedical Research
Structure-Based Approaches Uncover Distinct Binding Modes for Covalent and Non-Covalent Ligands
Alex Berndt, PhD, Structural Biologist, Astex Pharmaceuticals Ltd.
Integrating FBDD and DEL Approaches for Lead Generation
Chaohong Sun, PhD, Senior Director, Lead Discovery, AbbVie, Inc.
Beyond Affinity: Dissecting the Kinetic Landscape of Turnover Inhibitors of Nicotinamide N-Methyl Transferase (NNMT) and in vivo Verification of the Inhibitory Mechanism
Tomas Akerud, Associate Principal Scientist, Global Structural Chemistry, AstraZeneca R&D
Exploring Hidden Pockets: Using Experimentally Driven MD Simulations for Structure-Based Drug Design
Benjamin Walters, PhD, Senior Principal Scientist, Genentech, Inc.
Fragment Hit-Finding Campaigns against Ubiquitin Ligases
Charles Wartchow, PhD, Associate Director, Global Discovery Chemistry, Novartis Institutes for BioMedical Research
Search for Selective Inhibitors of Tau-Tubulin Kinase 1 (TTBK1) Using a Fragment-Based Lead-Discovery Approach
Sriram Tyagarajan, Associate Principal Scientist, Discovery Chemistry, Merck Sharp & Dohme
The Future Now: AI and Drug Discovery
Jose Duca, PhD, Global Head Computer Aided Drug Discovery, Global Discovery Chemistry, Novartis Institutes for Biomedical Research Inc.
Scale-Up Your Experts: Harnessing AI for Augmented Fragment-Based Drug Discovery
Marcel Verdonk, PhD, Senior Director, Computational Chemistry & Informatics, Astex Pharmaceuticals
Does AI Help DEL-Based Drug Discovery?
Jeff A. Messer, Director, Analytics, Encoded Libraries Technology, GlaxoSmithKline
Expanding the Chemical Space of DNA-Encoded Libraries in Two and Three Dimensions
Carol Mulrooney, PhD, Investigator, Cheminformatics, GlaxoSmithKline
Advancement and Application of DNA-Encoded Libraries at JNJ
Pratik R. Chheda, PhD, Scientist, DNA Encoded Library DEL, Janssen Pharmaceuticals
A Novel Method for Normalizing Data from DNA-Encoded Library Selections
Zsofia Lengyel-Zhand, PhD, Pfizer Inc.
HPK1 Citron Homology Domain Regulates Phosphorylation of SLP76 and Modulates Kinase Domain Interaction Dynamics
Laetitia D. Comps-Agrar, PhD, Senior Principal Scientist, Biochemical & Cellular Pharmacology, Genentech, Inc.
RIPK1 Inhibitors and Inflammation
Domagoj Vucic, PhD, Staff Scientist, Early Discovery Biology, Genentech, Inc.
Mechanistic Profiling for Protein Degraders
Hua Xu, PhD, Director, Mechanistic Biology & Profiling, AstraZeneca
Measuring Stable Interactions by SPR: Addressing the Long Residence-Time Challenge
Thomas P. Garner, PhD, Principal Scientist, Biophysics, Genentech, Inc.
Affinity Selection-Mass Spectrometry (ASMS) Applicability for PPI Targets
Hans-Peter N. Biemann, PhD, Distinguished Scientist, Integrated Drug Discovery, Sanofi
Fragment-Based Discovery of an Allosteric Phosphatase Modulator
Tom Davies, PhD, Director, Molecular Sciences, Astex Pharmaceuticals
Covalent Discovery at AstraZeneca: Delivering the Next Generation of Irreversible Medicines
Henry Blackwell, PhD, Senior Scientist, Medicinal Chemistry, AstraZeneca
Modeling Industrial ADME Datasets Using Multitask Neural Networks
Joe Napoli, PhD, Principal AI Scientist, DMPK, Genentech, Inc.
Discovery of HRO761, an Allosteric, First-in-Class Clinical WRN Inhibitor, Demonstrating Synthetic Lethality in MSI Cancers
Henrik Moebitz, PhD, Investigator III, Oncology & Exploratory Chemistry, Novartis Institutes for Biomedical Research
High-Throughput Encoded Peptide Discovery for Challenging Targets via mRNA Display
Christopher Stratton, PhD, Senior Scientist, Discovery Technologies & Molecular Pharmacology, Janssen Pharmaceuticals
DNA-Encoded Macrocyclic Libraries: Design and Case Study
Jack D. Scott, PhD, Director, Discovery Chemistry, Merck & Co.
Screening for Permeable Macrocyclic Peptides
Emel Adaligil, PhD, Senior Scientific Manager, Peptide Therapeutics, Genentech, Inc.
Identification of VEGF Antagonists for Retinal Angiogenesis Inhibition through Evolution of Disulfide Constrained Peptides (DCPs)
Xinxin Gao, PhD, Principal Scientific Manager, Peptide Therapeutics, Genentech, Inc.
PDL-1 Macrocyclic Inhibitor
Paul M. Scola, PhD, Group Director, Drug Discovery, Bristol Myers Squibb Co.
Discovery of an Orally Bioavailable Cyclic Peptide RAS Inhibitor Guided by Drug-Like Criteria
Atsushi Ohta, PhD, Head of Modality Technology Department, Chugai Pharmaceutical Co., Ltd.
* As of 12/11/2023 – Please see individual agenda pages for most up-to-date list of speakers